LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Kodu・Aktsiate loetelu・Guardant Health Inc

Guardant Health Inc

Suletud

SektorTervishoid

98.15 -0.3

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

99.34

Põhinäitajad
By Trading Economics
Sissetulek	16M -112M
Müük	20M 302M
Aktsiakasum	-0.45
Kasumimarginaal	-37.152
Töötajad	2,490
EBITDA	18M -101M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.88% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	29. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	737M 13B
Eelmine avamishind	98.45
Eelmine sulgemishind	98.15

Uudiste sentiment

By Acuity

50%

171 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

38.86 / 47.41 Toetus ja vastupanu

Guardant Health Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. mai 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. mai 2026, 22:12 UTC

Tulu

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. mai 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs

15. mai 2026, 00:00 UTC

Tulu

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. mai 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. mai 2026, 23:47 UTC

Tulu

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. mai 2026, 23:47 UTC

Tulu

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. mai 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. mai 2026, 22:00 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q EPS 18c >NU

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q Rev $4.97B >NU

Võrdlus sarnastega

Hinnamuutus

Guardant Health Inc Prognoos

Hinnasiht

By TipRanks

30.88% tõus

12 kuu keskmine prognoos

Keskmine 128.88 USD 30.88%

Kõrge 175 USD

Madal 92 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Guardant Health Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

Osta

Hoia

Müü

Põhineb 19 analüütiku instrumendi Guardant Health Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

38.86 / 47.41Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

171 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.